Active

NEUVASQ BIOTECHNOLOGIES

Switched

BE0762966663

Rechtspersoon Public limited company 2 establishments

Rue Auguste Piccard 48, 6041 Charleroi Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Active for

5 year, 7 months

Financials

Financial year 2025

Worth noting

  • A loss two years in a row.
  • Figures corrected afterwards (2024).

Gross margin

€ 641,586

▲ 15% vs 2024

Profit

Caution

€ -2.6 million

▼ 3% vs 2024

Debts

Low

€ 917,511

▲ 132% vs 2024

NEUVASQ BIOTECHNOLOGIES from Charleroi, company number BE0762966663, closed financial year 2025 with a result of € -2.6 million after tax. For that financial year NEUVASQ BIOTECHNOLOGIES recorded a gross margin of € 641,586 and equity of € 6.3 million. Compared with financial year 2024, the result moved from € -2.5 million to € -2.6 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.

What happened at NEUVASQ BIOTECHNOLOGIES?

What happened at NEUVASQ BIOTECHNOLOGIES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • GEMA SRL stepped down as director. NBB
  • Yves Ribeill stepped down as director. NBB
  • NEWTON BIOCAPITAL PARTNER SRL stepped down as director. NBB
  • Benoit Vanhollebeke stepped down as director. NBB
  • SPARAXIS SA stepped down as director. NBB
  • 50°NORTH VENTURES stepped down as director. NBB
  • SFPI SA stepped down as director. NBB
  • New annual accounts for financial year 2025: loss of € 2.6 million. Source: NBB ↗

In short

From € 463,776 loss in 2021 to € 2.6 million loss in 2025.

On average € 69,000 of value added per employee in 2025.

A new publication or filing at NEUVASQ BIOTECHNOLOGIES? We notify you, reason included.

Follow NEUVASQ BIOTECHNOLOGIES

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

Directors

According to the 2025 annual accounts

GEMA SRL

Chairman of the board · represented by Michel Allé

Also active at: D'Ieteren Group, EURVEST, EPICS THERAPEUTICS +2 more

since 2022 · until 2028

since 2025 · until 2027

Benoit Vanhollebeke

Director

since 2021 · until 2027

SPARAXIS SA

Director · represented by Christina Franssen

Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International +228 more

since 2021 · until 2027

50°NORTH VENTURES

Director · represented by Denis Bedoret

Also active at: EEBIC, BE ANGELS, Brussels South Charleroi BioPark Dev +18 more

since 2021 · until 2027

since 2025 · until 2027

Yves Ribeill

Director

since 2022 · until 2028

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Auguste Piccard 48

6041 Charleroi

2.338.878.351

Rue Adrienne Bolland 8

6041 Charleroi

Active since 1 January 2023

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number
0762.966.663
VAT number
BE 0762.966.663
Registered office
Rue Auguste Piccard 48, 6041 Charleroi
Names & denominations
NEUVASQ BIOTECHNOLOGIES
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
5 February 2021
Peppol
Active · Active since 15 Mar 2021
Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Activiteiten op het gebied van voeding

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Activiteiten van medische beeldvorming en medische laboratoria

Overige zakelijke dienstverlening, neg

+3

Frequently asked questions

What is the enterprise number of NEUVASQ BIOTECHNOLOGIES?
The enterprise number of NEUVASQ BIOTECHNOLOGIES is BE0762966663.
What is the address of NEUVASQ BIOTECHNOLOGIES?
The registered office of NEUVASQ BIOTECHNOLOGIES is located at Rue Auguste Piccard 48, 6041 Charleroi.
When was NEUVASQ BIOTECHNOLOGIES founded?
NEUVASQ BIOTECHNOLOGIES was founded on 5 February 2021.
What is the main activity of NEUVASQ BIOTECHNOLOGIES?
The main activity of NEUVASQ BIOTECHNOLOGIES is "Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied" (NACE code 72109).
Does NEUVASQ BIOTECHNOLOGIES have a website?
No website is currently known for NEUVASQ BIOTECHNOLOGIES.
How much profit did NEUVASQ BIOTECHNOLOGIES make in 2025?
NEUVASQ BIOTECHNOLOGIES recorded a loss after taxes of € 2,599,256 in financial year 2025.
What is the revenue of NEUVASQ BIOTECHNOLOGIES?
As a small company, NEUVASQ BIOTECHNOLOGIES is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 641,586.
How many employees does NEUVASQ BIOTECHNOLOGIES have?
According to the 2025 annual accounts, NEUVASQ BIOTECHNOLOGIES has 9.3 full-time equivalents (FTE).
Where can I find the annual accounts of NEUVASQ BIOTECHNOLOGIES?
NEUVASQ BIOTECHNOLOGIES files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of NEUVASQ BIOTECHNOLOGIES?
According to the 2025 annual accounts, the directors of NEUVASQ BIOTECHNOLOGIES are: GEMA SRL, NEWTON BIOCAPITAL PARTNER SRL, Benoit Vanhollebeke, SPARAXIS SA, 50°NORTH VENTURES, SFPI SA, Yves Ribeill.